AI assistant
KALA BIO, Inc. — Director's Dealing 2017
Jul 19, 2017
35091_dirs_2017-07-19_8ec60974-3bfd-4e4f-9632-82aee632a004.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-19
Reporting Person: Brazzell Romulus K (Chief Medical Officer, 10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.68 | 2023-05-10 | Common Stock (36094) | Direct | |
| Stock Option (right to buy) | $0.68 | 2023-05-10 | Common Stock (18048) | Direct | |
| Stock Option (right to buy) | $2.30 | 2024-10-02 | Common Stock (62560) | Direct | |
| Stock Option (right to buy) | $5.21 | 2025-10-02 | Common Stock (15430) | Direct | |
| Stock Option (right to buy) | $3.34 | 2026-06-17 | Common Stock (162135) | Direct |
Footnotes
F1: This option was granted on May 10, 2013 and vests over four years, with 25% of the shares underlying the option vested on January 1, 2014, and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
F2: This option was granted on May 10, 2013 and vests over four years, with 25% of shares underlying the option vesting 12 months after the date the Issuer submits an investigational new drug application for its loteprednol etabonate program and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
F3: This option was granted on October 2, 2014 and vests over four years, with 25% of the shares underlying the option vested on September 25, 2015 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
F4: This option was granted on October 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on October 2, 2016 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.
F5: This option was granted on June 17, 2016 and vests over four years, with 25% of the shares underlying the option vested on June 17, 2017 and an additional 2.0833% vesting at the end of each successive one-month period thereafter.